We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

B3SA3:BMFBOVESPAB3 SA - Brasil, Bolsa, Balcao Analysis

Data as of 2026-06-02 - not real-time

R$16.28

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

B3 S.A. delivers exceptional profitability with a 20% revenue growth year‑over‑year, gross margins above 95% and operating margins near 67%, while generating strong operating cash flow of over BRL 6.5 bn. The balance sheet shows ample liquidity (BRL 15 bn cash) against a debt level that, although sizable, is largely covered by cash, and the company returns 3.73% of its price in dividends with a 66% payout ratio, indicating sustainable income for shareholders.
On the price side, the stock trades at BRL 16.28, well below the DCF‑derived fair value of BRL 27.37, implying roughly 23% upside to the consensus target of BRL 20. Technicals are mixed: the price sits under the 20‑day and 50‑day SMAs, the MACD is bearish, and the RSI at 39 hints at possible oversold conditions, while support sits at BRL 15.81. High beta (~1.3) and 30‑day volatility above 34% suggest elevated market risk, but the sector’s regulated nature and solid dividend yield provide a stabilising backdrop.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price below short‑term moving averages indicating limited immediate upside
  • MACD bearish histogram and RSI near oversold levels
  • Positive earnings momentum from Q1 2026 call supporting stability

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF fair value suggests ~23% upside to current price
  • Strong cash generation and sustainable dividend yield
  • Analyst consensus target around BRL 20 with a buy recommendation

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Dominant market position in Brazil's exchange infrastructure
  • Consistently high profitability margins and revenue growth
  • Long‑term dividend sustainability and attractive yield

Key Metrics & Analysis

Financial Health

Revenue Growth20.30%
Profit Margin46.97%
P/E Ratio17.7
ROE26.74%
ROA9.24%
Debt/Equity85.24
P/B Ratio4.5
Op. Cash FlowR$6.6B
Free Cash FlowR$4.6B
Industry P/E16.6

Technical Analysis

TrendNeutral
RSI39.1
SupportR$15.81
ResistanceR$18.59
MA 20R$16.93
MA 50R$17.84
MA 200R$15.29
MACDBearish
VolumeStable
Fear & Greed Index93.27

Valuation

Fair ValueR$27.37
Target PriceR$20.04
Upside/Downside23.07%
GradeUndervalued
TypeBlend
Dividend Yield3.73%

Risk Assessment

Beta1.30
Volatility34.76%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.